Condition: Ovarian Neoplasms · Ovarian Cancer · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Mount Sinai Cancer Center ( Site 0029) | Miami Beach, Florida, United States | Recruiting |
| Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085) | Orlando, Florida, United States | Recruiting |
| Winship Cancer Institute of Emory University ( Site 0037) | Atlanta, Georgia, United States | Recruiting |
| Illinois Cancer Specialists (ICS) ( Site 8009) | Arlington Heights, Illinois, United States | Recruiting |
| Parkview Research Center at Parkview Regional Medical Center ( Site 0055) | Fort Wayne, Indiana, United States | Recruiting |
| Women's Cancer Care ( Site 0018) | Covington, Louisiana, United States | Recruiting |
| Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0060) | Scarborough, Maine, United States | Recruiting |
| Nebraska Methodist Hospital ( Site 0004) | Omaha, Nebraska, United States | Recruiting |
| University Of Nebraska Medical Center ( Site 0035) | Omaha, Nebraska, United States | Recruiting |
| University of Cincinnati Medical Center ( Site 0042) | Cincinnati, Ohio, United States | Recruiting |
| Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007) | Tulsa, Oklahoma, United States | Recruiting |
| Women & Infants Hospital ( Site 0001) | Providence, Rhode Island, United States | Recruiting |
+ 123 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07318558